摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

防己菲碱 | 22108-99-2

中文名称
防己菲碱
中文别名
——
英文名称
stephenanthrine
英文别名
Phenanthro(3,4-d)-1,3-dioxole-5-ethanamine, N,N-dimethyl-;N,N-dimethyl-2-naphtho[2,1-g][1,3]benzodioxol-5-ylethanamine
防己菲碱化学式
CAS
22108-99-2
化学式
C19H19NO2
mdl
——
分子量
293.365
InChiKey
FXTBDJZGDJJCQU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    81-82 °C
  • 沸点:
    465.2±24.0 °C(Predicted)
  • 密度:
    1.212±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:1fb973034d3080ccdcfde7a4f7b6d805
查看

反应信息

  • 作为产物:
    描述:
    番荔枝碱 在 potassium hydroxide 作用下, 以 甲醇乙醚 为溶剂, 反应 14.0h, 生成 防己菲碱
    参考文献:
    名称:
    PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS
    摘要:
    本发明涉及苯并并芘衍生物作为药物的用途,主要用于预防和/或治疗肌无力型1型、亨廷顿病类2型、脊髓小脑共济失调型8型、肌无力型2型、脊髓小脑共济失调型3型、脆性X相关震颤/共济失调综合征、额颞叶退行性/肌萎缩侧索硬化和脊髓小脑共济失调型31型。在一个首选实施例中,本发明的苯并并芘衍生物也用作抗肌无力剂。因此,本发明可包括在整个制药或医学领域中。
    公开号:
    US20160194274A1
点击查看最新优质反应信息

文献信息

  • Phenanthrene derivatives for use as medicaments
    申请人:Valentia Biopharma
    公开号:EP2742974A1
    公开(公告)日:2014-06-18
    Phenanthrene derivatives of formula I for use as medicaments. The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of DM1, HDL2, SCA8, DM2, SCA3, FXTAS, FTD/ALS, and SCA31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents.
    公式I的菲南三烯衍生物用作药物。本发明涉及用作药物的菲南三烯衍生物,主要用于预防和/或治疗DM1、HDL2、SCA8、DM2、SCA3、FXTAS、FTD/ALS和SCA31。在一个优选实施例中,本发明的菲南三烯衍生物也用作抗肌肉张力剂。
  • THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES
    申请人:RICCIARDI Robert P.
    公开号:US20100035887A1
    公开(公告)日:2010-02-11
    This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.
    本发明提供了一种通过将痘病毒与具有公式I、公式XXI、公式XXXII或公式XLI的化合物接触来抑制痘病毒复制的方法,进而减少、抑制或消除痘病毒DNA聚合酶活性和/或其与其过程性因子的相互作用。公式I、公式XXI、公式XXXII或公式XLI可用于治疗患有痘病毒感染的人类和动物。还提供了用于治疗痘病毒感染受试者的药物组合物。
  • Hofmann Elimination with Diazomethane on Quaternary Benzyltetrahydroisoquinoline Related Alkaloids
    作者:Sheng-Teh Lu、Ian-Lih Tsai
    DOI:10.3987/com-87-4416
    日期:——
  • Konstitution und Synthese des Alkaloids Anonain
    作者:G. Barger、G. Weitnauer
    DOI:10.1002/hlca.193902201131
    日期:——
  • Konowalowa et al., Bulletin de la Societe Chimique de France, 1939, vol. <5> 6, p. 811,815
    作者:Konowalowa et al.
    DOI:——
    日期:——
查看更多

同类化合物

防己菲碱 绿唐松草酮 N-去甲基芒籽宁 N,N-二甲基-2-芘-1-基乙胺 ATM44-乙酰氧基类似物 3,4-二甲氧基-N,N-二甲基-1-菲乙胺 trimethyl-(2-oxo-2-pyrene-1-yl-ethyl)-ammonium bromide dimethyl-(2-[1]phenanthryl-ethyl)-amine secocrebanine N-allylsecoboldine 4-Phenanthrenol, 1-(2-(dimethylamino)ethyl)-3,5,6-trimethoxy- 1-(2-Dimethylaminoethyl)-3,6,7-trimethoxyphenanthren-4-ol [2-(5,6-Dihydroxy-phenanthren-1-yl)-ethyl]-methyl-cyanamide 8-[2-[ethyl(methyl)amino]ethyl]-9,10-dihydrophenanthrene-3,4-diol;hydron;bromide 3,4-Phenanthrenediol, 8-(2-(ethylmethylamino)ethyl)-, hydrobromide Acetic acid 5-[2-(cyano-methyl-amino)-ethyl]-10-methoxy-phenanthro[3,4-d][1,3]dioxol-11-yl ester 3,4,5,6-Tetramethoxy-1-(dimethylamino-ethyl)-phenanthren 8-(2-Dimethylamino-ethyl)-phenanthrene-3,4-diol 3,4-Phenanthrenediol, 8-(2-(dimethylamino)ethyl)-, hydrobromide 2.3.5.6-Tetramethoxy-8-<2-dimethylamino-aethyl>-phenanthren-methojodid Dicentrin-methin II N-[2-(9-methoxynaphtho[2,1-g][1,3]benzodioxol-5-yl)ethyl]-N-methylhydroxylamine 1-<2-ethyl>-3,4,6,7-tetramethoxyphenantrene N-carbethoxy-N-methyl-2-(3',4'-dimethoxy-1'-phenanthryl)ethylamine N-benzylsecoboldine [2-(10,11-dimethoxy-phenanthro[3,4-d][1,3]dioxol-5-yl)-ethyl]-dimethyl-amine secoroemerine N-carbethoxysecoglaucine Ethyl-methyl-(2-naphtho[2,1-g][1,3]benzodioxol-5-ylethyl)azanium N-benzyl-2-(3,7-dibutoxy-4,6-dimethoxyphenanthren-1-yl)-N-methylethanamine Dimethyl-[2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethyl]azanium Dimethyl(2-naphtho[2,1-g][1,3]benzodioxol-5-ylethyl)azanium 8-[2-(dimethylamino)ethyl]-9,10-dihydrophenanthrene-3,4-diol;hydron;bromide N,N-dimethyl-2-pyren-1-ylpropan-1-amine 2-(3,4-Dihydroxyphenanthren-1-yl)ethyl-trimethylazanium N,N-dimethyl-2-[(6R)-6-methyl-6,7-dihydronaphtho[2,1-g][1,3]benzodioxol-5-yl]ethanamine N,N-dimethyl-2-(3,4,6,7-tetramethoxy-6,7-dihydrophenanthren-1-yl)ethanamine N,N-dimethyl-2-[(10R)-3,4,6,7-tetramethoxy-10-methyl-9,10-dihydrophenanthren-1-yl]ethanamine Trimethyl(2-naphtho[2,1-g][1,3]benzodioxol-5-ylethyl)azanium Ethyl-methyl-(2-phenanthro[3,4-d][1,3]dioxol-5-yl-ethyl)-amine (1S)-2-(dimethylamino)-1-naphtho[2,1-g][1,3]benzodioxol-5-ylethanol Trimethyl-[2-(2,3,4-trimethoxyphenanthren-1-yl)ethyl]azanium 3,6-Dimethoxy-4-hydroxy-8-<2-(N-methyl-N-ethylamino)ethyl>phenanthrene [2-(5,6-dimethoxy-9,10-dihydro-[1]phenanthryl)-ethyl]-dimethyl-amine 8-[2-(Dimethylamino)ethyl]-3,5-dimethoxyphenanthrene-2,6-diol 2-bromosecoboldine 2-bromo-N,N-dimethylsecoboldine iodide 2-bromo-3,7-dimethoxy-N,N-dimethylsecoboldine iodide 2-bromo-N-methylsecoboldine